HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Bosse, D. Articles by Schindel, F. Search for Related Content PubMed PubMed Citation Articles by Bosse, D. Articles by Schindel, F.

Phase I Comparability of Recombinant Human Albumin and Human Serum Albumin

From ZLB Behring, Marburg, Germany (Dr Bosse, Dr Kiessling); Covidence, Marburg, Germany (Ms Praus, Mr Schindel); Quintiles, Uppsala, Sweden (Dr Nyman); Alza Corporation, Mountain View, California (Dr Andresen); and Delta Biotechnology Ltd., Nottingham, United Kingdom (Ms Waters).

Recombinant human albumin (rHA) is a highly purified animal-, virus-, and prion-free product developed as an alternative to human serum albumin (HSA), to which it is structurally equivalent. The present investigation compared the safety, tolerability, and pharmacokinetics/pharmacodynamics of rHA with HSA. Two double-blind, randomized trials were performed in healthy volunteers using intramuscular (IM) and intravenous (IV) administration. The IM trial included 500 volunteers, each receiving 5 repeat doses of 5 mg (100 subjects), 15 mg (100 subjects), or 65 mg (300 subjects) of rHA or HSA. Thirty volunteers participated in the IV trial, each receiving ascending doses (10 g, 20 g, and 50 g) of either rHA or HSA. In both trials, all adverse events were recorded and conventionally classified; potential allergic responses were also monitored. Blood samples were taken in both studies to test for IgG or IgE antibodies against test products and potential impurities. For the IV study, pharmacokinetic/pharmacodynamic assessments were performed, including measurement of serum albumin, colloid osmotic pressure, and hematocrit pre- and postinfusion. Nine subjects in the IM study (4 recipients of rHA and 5 of HSA) reported drug-related, potentially allergic events; all but 2 of these were skin related. No serious or potentially allergic events were reported with either product in the IV study. There was no immunological response to either product, and dose level did not influence the study outcomes. Serum albumin, colloid osmotic pressure changes, and hematocrit ratio were as expected, with no differences between rHA and HSA. rHA and HSA exhibited similar safety, tolerability, and pharmacokinetic/pharmacodynamic profiles, with no evidence of any immunological response.

Key Words: Recombinant human albumin • human serum albumin • drug safety • pharmacokinetics • pharmacodynamics

Address for reprints: Peter Kiessling, PhD, ZLB Behring, Marburg, Germany.

This article has been cited by other articles:

				K. Ohnishi, A. Kawaguchi, S. Nakajima, H. Mori, and T. Ueshima A Comparative Pharmacokinetic Study of Recombinant Human Serum Albumin With Plasma-derived Human Serum Albumin in Patients With Liver Cirrhosis J. Clin. Pharmacol., February 1, 2008; 48(2): 203 - 208. [Abstract] [Full Text] [PDF]